United Therapeutics Corporation (NASDAQ:UTHR) Q1 2023 Earnings Conference Call May 3, 2023 9:00 AM ET

Company Participants

Dewey Steadman - Head-Investor Relations

Martine Rothblatt - Chairperson and Chief Executive Officer

Michael Benkowitz - President and Chief Operating Officer

James Edgemond - Chief Financial Officer and Treasurer

Pat Poisson - Executive Vice President of Technical Operations

Leigh Peterson - Senior Vice President of Product Development

Conference Call Participants

Joseph Thome - TD Cowen and Company

Hartaj Singh - Oppenheimer & Co.

Jessica Fye - JPMorgan

Eun Yang - Jefferies

Andreas Argyrides - Wedbush Securities

Ashwani Verma - UBS

Operator

Good morning, and welcome to the United Therapeutics Corporation First Quarter 2023 Earnings Webcast. My name is Danielle, and I will be your conference operator today. [Operator Instructions] Please note this call is being recorded. I would now like to turn the webcast over to Dewey Steadman, Head of Investor Relations at United Therapeutics.

Dewey Steadman

Thank you, Danielle, and good morning. It's my pleasure to welcome you to the United Therapeutics Corporation First Quarter 2023 Earnings Webcast. Accompanying me on today's call are Dr. Martine Rothblatt, our Chairperson and Chief Executive Officer; Michael Benkowitz, our President and Chief Operating Officer; James Edgemond, our Chief Financial Officer and Treasurer; and then Pat Poisson, our Executive Vice President of Technical Operations; and finally, Dr. Leigh Peterson, our Senior Vice President of Product Development.

Remarks today will include forward-looking statements representing our expectations or beliefs regarding future events. These statements involve risks and uncertainties that may cause actual results to differ materially. Our latest SEC filings, including Forms 10-K and 10-Q contain additional information on these risks and uncertainties, and we assume no obligation to update these forward-looking statements.

Today's remarks also may discuss the progress and results of clinical trials or other developments with respect to our products. These remarks are intended solely to educate investors and are not intended to serve as the basis for medical decision-making or to suggest that any products are safe and effective for any unapproved or investigational uses. Full prescribing information for these products are available on the product's website.

Now I will turn the webcast over to Dr. Rothblatt for an overview of our first quarter 2023 financial results and the business activities of United Therapeutics. Martine?

Martine Rothblatt

Thank you, Dewey. Very excited to welcome everyone to another great quarter at United Therapeutics. We are thrilled to continue on course towards our mid-decade goals of 25,000 patients being treated for pulmonary hypertension and the doubling of our revenue run rate.